Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Latest quarter Q3 FY2026 · quarter to September 2026

Line Q3 FY26 On Q3 FY25 Against consensus
Revenue $449.1K on Q3 FY25 −61.4% —
Operating margin −403.6% on Q3 FY25 −238.2 pts —
EPS, diluted −$0.04 on Q3 FY25 n/m Missed by $0.02adjusted −$0.05 v −$0.03
Each line over the last 8 quarters
LineQ4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$817.4K$393.6K$966.6K$1.2M$565.5K$1.1M$961.1K$449.1K
Operating margin−188.4%−505.2%−178.9%−165.3%−274.1%−171.3%−213.7%−403.6%
EPS, diluted−$0.05−$0.07−$0.06−$0.06−$0.06−$0.05−$0.06−$0.04

The consensus is analysts’ estimate of revenue and of adjusted EPS.

Revenue growth on a year earlier

Revenue growth has slowed two quarters running, from 182% to -61%.

Revenue growth on a year earlier, by quarter
Q4 FY2419%
Q1 FY2518%
Q2 FY25150%
Q3 FY25−41%
Q4 FY25−31%
Q1 FY26182%
Q2 FY26−1%
Q3 FY26−61%

Reports 24 Mar 2027 · Q4 FY26 · consensus EPS −$0.02

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 14
Revenue ttm 3
Net income ttm (7)
Free cash flow ttm (7)
Net debt Q 0
Valuation
P/E n/m
Forward P/E FY26e n/m
Price / sales 4.0
Forward P/S FY26e Powerpack
Price / FCF n/m
Price / book n/m
Financial health
Current ratio Q 1.7 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (18.8)
Growth
Revenue growth FY26e +113.2% (at or above 10%: strong)
EPS growth FY26e +39.1% (at or above 15%: strong)
EPS growth FY27e +121.4% (at or above 15%: strong)
EPS growth, 5 yrs e +64.8% (at or above 15%: strong)
Insiders
Net sold 12m 0
Sells 12m 1
Buys 12m 0
Owned by insiders 19.5%
Compound annual growth
10y 5y 3y
Sales 25.61% 14.04% 1.79%
Cash Flow — 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value — (46.62%) (51.92%)

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation

P/S against its own 10 years 0.20%
10-year low 10-year high
EV/Sales against its own 10 years 2.81%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 1 1 2 2 2 3 3 3 3 3 +20.1% 7 13 17 +75.7%
Gross margin, % 100.00 10.31 20.70 13.17 11.05 19.11 27.54 31.84 65.82 24.93 17.85 (75.1) pt
EBT 1 (2) (7) (8) (9) (13) (10) (7) (6) (7) (7) n/m
EBT margin, % 100.00 (290.41) (517.01) (493.59) (580.19) (543.73) (332.23) (234.42) (166.20) (238.31) (226.87) (338.3) pt
Net income 0 (2) (6) (8) (9) (13) (10) (7) (6) (7) (7) n/m
Per share, $
Per share, $ Revenue 0.02 0.03 0.05 0.06 0.06 0.09 0.10 0.10 0.12 0.09 0.08 +21.7%
Earnings (0.10) (0.07) (0.21) (0.31) (0.34) (0.47) (0.34) (0.24) (0.20) (0.23) (0.21) +9.7%
Cash flow (0.17) (0.06) (0.16) (0.21) (0.24) (0.41) (0.28) (0.23) (0.14) (0.17) (0.18) +0.6%
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Free cash flow (0.17) (0.06) (0.16) (0.21) (0.24) (0.41) (0.28) (0.23) (0.14) (0.17) (0.18) +0.6%
Book value 1.58 1.73 1.53 1.33 1.04 0.66 0.39 0.20 0.08 0.04 (0.07) (33.9%)
Shares, m 37 29 28 27 27 28 28 29 29 33 36 (1.3%)
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 63.08 40.39 83.21 92.26 52.35 13.36 15.80 14.68 9.92 3.97 38.5
P/B 0.00 0.96 1.23 3.90 5.20 6.84 3.53 7.79 20.77 24.88 0.00 7.5
EV/Sales (8.35) 0.25 8.57 62.85 74.10 43.92 9.04 13.33 13.45 8.78 4.09 22.6
EV/FCF 0.00 (0.15) (2.46) (17.93) (17.76) (9.27) (3.23) (5.65) (11.51) (4.67) (1.77) (7.3)
Cash, $m
Cash, $m Operating cash flow (6) (2) (4) (6) (7) (11) (8) (7) (4) (6) (7) (0.6%)
Capex — — — — — — — — — — 0 —
Free cash flow (6) (2) (4) (6) (7) (11) (8) (7) (4) (6) (7) (0.6%)
Balance, $m
Balance, $m Working capital 57 49 42 34 28 18 11 6 7 6 3 (21.8%)
Net debt (56) (48) (41) (34) (29) (20) (13) (7) (4) (4) 0 (26.5%)
Shareholders’ equity 58 50 42 36 28 18 11 6 2 1 (3) (34.8%)
Returns, %
Returns, % ROA 0.00 (8.42) (12.10) (20.58) (27.62) (50.89) (55.61) (61.97) (64.01) (74.11) (71.43) (74.1) pt
ROIC 26.74 20.70 (380.11) (353.37) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (26.7) pt
ROE (12.14) (3.97) (12.32) (21.22) (29.00) (55.81) (66.05) (80.11) (139.16) (397.80) (47,310.78) (385.7) pt
People
People Employees — — 6 6 6 7 7 7 6 5 — (2.6%)
Revenue/emp, $m 0.00 0.00 0.22 0.28 0.27 0.34 0.42 0.41 0.58 0.62 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 13 Nov 2026

Dyadic International Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ALLR Allarity Therapeutics, Inc. $14.5M — (loss-making) — (loss-making) — n/m +15.63% (above 0%: growing) 100.00% (110,140.00%) Compare
NCEL NewcelX Ltd. $14.5M — (loss-making) — — — −87.71% (below 0%: shrinking) 0.00% — Compare
QNTM Quantum Biopharma Ltd. $14.4M — (loss-making) — (loss-making) — n/m +5.88% (above 0%: growing) 0.00% 0.00% Compare
MCRB Seres Therapeutics, Inc. $14.4M — (loss-making) — (loss-making) +68.95% (above 0%: growing) n/m −574.29% (below 0%: shrinking) 100.00% (2,723.78%) Compare
DYAI Dyadic International Inc. $14.0M — (loss-making) — (loss-making) −61.44% (below 0%: shrinking) n/m +19.88% (above 0%: growing) 16.47% (403.55%)
NEUP Neuphoria Therapeutics Inc. $14.0M — (loss-making) — (loss-making) −107.32% (below 0%: shrinking) n/m +133.86% (above 0%: growing) 100.00% 0.00% Compare
ALGS Aligos Therapeutics, Inc. $14.0M — (loss-making) — (loss-making) +287.18% (above 0%: growing) n/m +105.40% (above 0%: growing) 100.00% (762.98%) Compare
LSTA Lisata Therapeutics, Inc. $13.8M — (loss-making) — (loss-making) −98.30% (below 0%: shrinking) n/m +33.04% (above 0%: growing) 100.00% 0.00% Compare
PLUR Pluri Inc. $13.7M — (loss-making) — (loss-making) +140.19% (above 0%: growing) n/m +18.00% (above 0%: growing) 55.34% (2,051.25%) Compare
Median of peers $14.2M — — +68.95% — +16.82% 100.00% (762.98%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 12 May 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.01m 518.55k 76.42
2024 1.04m 1.08m 39.77
2023 1.04m 1.11m 29.93
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Dyadic International Inc. (DYAI) Latest News

What happened

Share price over the fortnight −13.0%
  1. Results Dyadic reported third-quarter revenue of $449,101, down 61% year over year, and a $1.36 million net loss.
  2. Product Dyadic’s C1-produced RSV and malaria antibodies advanced into mouse pharmacokinetic studies comparing them with CHO-produced versions.
  3. Deal Dyadic, BRIG BIO and Strive Nutrition agreed to develop precision-fermented alpha-lactalbumin, targeting initial supply above 10 metric tonnes.
17 more headlines
All DYAI news, as stories →
stockrow.com/DYAI · Data as of Nov 13, 2026 · For information only; not investment advice. · © 2026 stockrow.com